Literature DB >> 9227302

Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy.

J J Crowley1, P S Dardas, A A Harcombe, L M Shapiro.   

Abstract

OBJECTIVE: To use transthoracic Doppler echocardiography to assess coronary blood flow non-invasively in patients with hypertrophic cardiomyopathy.
DESIGN: High frequency transthoracic Doppler echocardiography was used to assess resting phasic coronary velocity patterns in patients with hypertrophic cardiomyopathy and to define the relation between coronary flow patterns and clinical, echocardiographic, and haemodynamic manifestations of this condition.
SETTING: A tertiary referral cardiothoracic centre.
METHODS: Fifteen patients (10 men and five women, mean (SD) age 49 (10.3) years) with asymmetric hypertrophic cardiomyopathy underwent high frequency (5 MHz) transthoracic Doppler echocardiographic assessment of the left anterior descending coronary artery. In addition, standard two dimensional echocardiography was performed. The results were compared with 16 normal participants (nine men and seven women, mean age 61.2 (10.7) years) who had no evidence of cardiac disease.
RESULTS: Biphasic diastolic predominant coronary artery blood velocity profiles were obtained in all patients and controls. Systolic peak blood velocity and velocity time integral were significantly reduced in the hypertrophic cardiomyopathy group compared with controls (11.3 (15.8) cm/s and 1.09 (1.78) cm v 20.5 (13.1) cm/s and 4.23 (2.80) cm, respectively, P < 0.05). A reversed pattern of systolic blood flow velocity was found in three patients with severe anterior wall and septal hypertrophy. During diastole there was prolongation of the diastolic acceleration (203 (53) ms v 110 (60) ms in controls, P < 0.05) and deceleration times (487 (200) ms v 210 (90) ms in controls, P < 0.05). There was no significant difference between those with and without symptoms or a left ventricular outflow tract gradient.
CONCLUSIONS: Patients with hypertrophic cardiomyopathy have abnormal systolic and diastolic coronary flow profiles at rest when measured by transthoracic echocardiography.

Entities:  

Mesh:

Year:  1997        PMID: 9227302      PMCID: PMC484801          DOI: 10.1136/hrt.77.6.558

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  36 in total

1.  Myocardial thallium 201 imaging in hypertrophic obstructive cardiomyopathy.

Authors:  P Hanrath; D Mathey; R Montz; U Thiel; H Vorbringer; W Kupper; C Schneider; W Bleifeld
Journal:  Eur Heart J       Date:  1981-06       Impact factor: 29.983

2.  Phasic coronary blood flow velocity in intramural and epicardial coronary arteries.

Authors:  W M Chilian; M L Marcus
Journal:  Circ Res       Date:  1982-06       Impact factor: 17.367

Review 3.  Hypertrophic cardiomyopathy: subclassification by m mode echocardiography.

Authors:  B W Gilbert; C Pollick; A G Adelman; E D Wigle
Journal:  Am J Cardiol       Date:  1980-04       Impact factor: 2.778

4.  Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries.

Authors:  A Pasternac; J Noble; Y Streulens; R Elie; C Henschke; M G Bourassa
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

5.  Noninvasive assessment and differentiation of left ventricular outflow obstruction with Doppler ultrasound.

Authors:  L Hatle
Journal:  Circulation       Date:  1981-08       Impact factor: 29.690

6.  Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis.

Authors:  M G St John Sutton; J T Lie; K R Anderson; P C O'Brien; R L Frye
Journal:  Br Heart J       Date:  1980-10

7.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

8.  Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries.

Authors:  D Opherk; G Mall; H Zebe; F Schwarz; E Weihe; J Manthey; W Kübler
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

9.  Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy.

Authors:  M Tanaka; H Fujiwara; T Onodera; D J Wu; Y Hamashima; C Kawai
Journal:  Br Heart J       Date:  1986-06

10.  Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures.

Authors:  R O Cannon; D R Rosing; B J Maron; M B Leon; R O Bonow; R M Watson; S E Epstein
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

View more
  5 in total

1.  Diastolic flow velocity pattern of the left anterior descending coronary artery in hypertrophied heart, with special reference to the difference between hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy.

Authors:  Nobuo Fukuda; Yamato Fukuda; Satofumi Morishita; Koichi Sakabe; Hisanori Shinohara; Yoshiyuki Tamura
Journal:  J Echocardiogr       Date:  2010-01-13

2.  Systolic compression of epicardial coronary and intramural arteries in children with hypertrophic cardiomyopathy.

Authors:  Saidi A Mohiddin; Lameh Fananapazir
Journal:  Tex Heart Inst J       Date:  2002

Review 3.  [Methods for coronary functional assessment].

Authors:  M Elsner
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

4.  Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  P Petkow Dimitrow; M Krzanowski; R Nizankowski; A Szczeklik; J S Dubiel
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

Review 5.  Transthoracic Doppler echocardiography - noninvasive diagnostic window for coronary flow reserve assessment.

Authors:  Paweł Petkow Dimitrow
Journal:  Cardiovasc Ultrasound       Date:  2003-04-11       Impact factor: 2.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.